Pfanstiehl is a global leader in the manufacture of cGMP-produced, high purity, injectable grade excipients and bioprocessing solutions. The majority of leading biopharma firms trust Pfanstiehl to supply them with critical formulation components for their commercial manufacturing needs.
Pfanstiehl Launches New cGMP-produced, Parenteral Grade Histidine and Histidine HCl For Biopharmaceutical Formulations
Following a record 100th year in business, Pfanstiehl has launched high purity, low endotoxin, low metal L-Histidine and L-Histidine Hydrochloride Monohydrate and established a new quality
Pfanstiehl Launches a new cGMP-produced, Parenteral Grade Sodium Succinate (Hexahydrate) for Biopharmaceutical and Pharmaceutical Formulations
Pfanstiehl has announced the launch of the first cGMP Sodium Succinate Hexahydrate (NF) to the market, which is compliant with the new USP Monograph established in 2017. Pfanstiehl previously launched
Pfanstiehl Launches a new cGMP-produced, Parenteral Grade Arginine For Biopharmaceutical and Pharmaceutical Formulations
As Pfanstiehl approaches its 100th anniversary in 2019, the company has launched a new high purity, low endotoxin, and low metal L-Arginine (USP, EP, JP, ChP),